Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Increasing options for the treatment of osteoporosis.

Literature DB >> 19671654

Increasing options for the treatment of osteoporosis.

Sundeep Khosla.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19671654 PMCID： PMC3901579 DOI： 10.1056/NEJMe0905480

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

11 in total

1. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors: D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal: Cell Date: 1998-04-17 Impact factor: 41.582

2. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245

3. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245

Review 4. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

Authors: Ethel S Siris; Peter L Selby; Kenneth G Saag; Fredrik Borgström; Ron M C Herings; Stuart L Silverman
Journal: Am J Med Date: 2009-02 Impact factor: 4.965

Review 5. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors: R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal: Osteoporos Int Date: 2008-06 Impact factor: 4.507

6. Denosumab in postmenopausal women with low bone mineral density.

Authors: Michael R McClung; E Michael Lewiecki; Stanley B Cohen; Michael A Bolognese; Grattan C Woodson; Alfred H Moffett; Munro Peacock; Paul D Miller; Samuel N Lederman; Charles H Chesnut; Douglas Lain; Alan J Kivitz; Donna L Holloway; Charlie Zhang; Mark C Peterson; Pirow J Bekker
Journal: N Engl J Med Date: 2006-02-23 Impact factor: 91.245

7. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741

8. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors: Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245

9. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors: Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245

Review 10. Building bone to reverse osteoporosis and repair fractures.

Authors: Sundeep Khosla; Jennifer J Westendorf; Merry Jo Oursler
Journal: J Clin Invest Date: 2008-02 Impact factor: 14.808

27 in total

1. Approaches to treating osteoporosis.

Authors: Athol Kent
Journal: Rev Obstet Gynecol Date: 2009

Review 2. Measuring and improving adherence to osteoporosis pharmacotherapy.

Authors: Suzanne M Cadarette; Andrea M Burden
Journal: Curr Opin Rheumatol Date: 2010-07 Impact factor: 5.006

3. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures.

Authors: Wei-Min Deng; Peng Zhang; Hai Huang; You-Gao Shen; Qin-Hua Yang; Wei-Li Cui; Yang-Shu He; Song Wei; Zhu Ye; Fang Liu; Ling Qin
Journal: J Bone Miner Metab Date: 2012-06-22 Impact factor: 2.626

Increasing options for the treatment of osteoporosis.

1. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

2. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

3. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Review 4. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

Review 5. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

6. Denosumab in postmenopausal women with low bone mineral density.

7. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

8. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

9. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Review 10. Building bone to reverse osteoporosis and repair fractures.

1. Approaches to treating osteoporosis.

Review 2. Measuring and improving adherence to osteoporosis pharmacotherapy.

3. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures.

4. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

Review 5. New treatment modalities in osteoporosis.

6. Bone loss and fractures in limbs paralyzed by spinal cord injury: Prevention, diagnosis, and treatment.

Review 7. Intravenous zoledronate for osteoporosis: less might be more.

8. Is nitroglycerin a novel and inexpensive treatment for osteoporosis?

Review 9. Update on estrogens and the skeleton.

Review 10. Nuclear receptors in bone physiology and diseases.